Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.87USD
11:07pm IST
Change (% chg)

$-0.10 (-5.08%)
Prev Close
$1.97
Open
$1.94
Day's High
$1.94
Day's Low
$1.87
Volume
29,261
Avg. Vol
56,472
52-wk High
$3.35
52-wk Low
$0.87

Select another date:

Thu, Jul 2 2020

BRIEF-Aspire Capital Fund Reports 19.89% Passive Stake In Akari Therapeutics - SEC Filing

* ASPIRE CAPITAL FUND LLC REPORTS 19.89% PASSIVE STAKE IN AKARI THERAPEUTICS PLC AS OF JULY 1 - SEC FILING Source text for Eikon: https://bit.ly/3eT7bFx Further company coverage:

BRIEF-Akari Therapeutics Appoints Chief Financial Officer

* AKARI THERAPEUTICS ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

BRIEF-Akari Therapeutics Enters Into A Securities Purchase Agreement For Up To $30 Mln With Aspire Capital Fund

* AKARI THERAPEUTICS ENTERS INTO A SECURITIES PURCHASE AGREEMENT FOR UP TO $30 MILLION WITH ASPIRE CAPITAL FUND, LLC

BRIEF-Akari Therapeutics Reports Qtrly Loss Per Share $0.00

* AKARI THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

BRIEF-Akari Therapeutics Receives Positive EMA Opinion On Orphan Designation For Nomacopan For Bullous Pemphigoid

* AKARI THERAPEUTICS RECEIVES POSITIVE EMA OPINION ON ORPHAN DESIGNATION FOR NOMACOPAN FOR BULLOUS PEMPHIGOID

BRIEF-Akari Therapeutics Announces Positive Topline Results From Phase II Study Of Nomacopan In Bullous Pemphigoid Patients

* AKARI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM FULLY RECRUITED PHASE II STUDY OF NOMACOPAN IN BULLOUS PEMPHIGOID PATIENTS

BRIEF-Akari Reports Fourth Quarter Results

* AKARI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Akari Therapeutics Plc Files Prospectus Relates To Resale, By Selling Shareholders Of Up To 765.6 Million Ordinary Shares

* AKARI THERAPEUTICS PLC FILES PROSPECTUS RELATES TO RESALE, BY SELLING SHAREHOLDERS OF UP TO 765.6 MILLION ORDINARY SHARES - SEC FILING Source text: (https://bit.ly/2UkMRF3) Further company coverage:

BRIEF-Akari Therapeutics Announces Private Placement

* AKARI THERAPEUTICS PLC - WILL ISSUE UNREGISTERED ADSS AT A PURCHASE PRICE OF $1.70 PER ADS Source text for Eikon: Further company coverage:

BRIEF-Akari Therapeutics Announces Private Placement

* AKARI THERAPEUTICS - ENTERED INTO AGREEMENTS WITH CERTAIN INVESTORS, INCLUDING RAY PRUDO, CO’S CHAIRMAN, TO RECEIVE GROSS PROCEEDS OF ABOUT $6 MILLION THROUGH PRIVATE PLACEMENT Source: (https://bit.ly/2VaUb7k) Further company coverage:

Select another date: